Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

The creatively structured deal adds Amylin’s GLP-1 franchise and other assets to the two pharmas’ diabetes portfolio.

You may also be interested in...



Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge

Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.

AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story

FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.

Lilly Brings Non-Inferiority Data To GLP-1 Show Down

In the competitive GLP-1 market, non-inferiority data against Novo Nordisk’s market-leading Victoza will go a long way toward strengthening the commercial case for Lilly’s once-weekly GLP-1, dulaglutide, pending at FDA.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel